Details of the Drug

General Information of Drug (ID: DMMIQ7G)

Drug Name

Rosuvastatin

Synonyms

Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[2]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[1]
Hypertriglyceridemia	5C80.1	Approved	[1]
Elevated C-reactive protein	MA14.15	Phase 3	[2]
Colon cancer	2B90.Z	Investigative	[1]
Precancerous condition	N.A.	Investigative	[1]
Stroke	8B20	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticholesteremic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

481.5

Logarithm of the Partition Coefficient (xlogp)

1.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 6.06 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: The bioavailability of drug is 20% [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [5]
Elimination: Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 19 hours []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.18665 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.12% [5]
Vd: The volume of distribution (Vd) of drug is 134 L []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiovascular disorder	rs20455	KIF6	OTDH3MR4	[7]
LDL cholesterol decreased	rs2231142	ABCG2	OTW8V2V1	[8]
LDL cholesterol increased	rs17244841	HMGCR	OTRT3F3U	[9]
-----------

Chemical Identifiers

Formula: C22H28FN3O6S
IUPAC Name: (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
Canonical SMILES: CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
InChI: InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
InChIKey: BPRHUIZQVSMCRT-VEUZHWNKSA-N

Cross-matching ID

PubChem CID: 446157
ChEBI ID: CHEBI:38545
CAS Number: 287714-41-4
DrugBank ID: DB01098
TTD ID: D0JE2E
VARIDT ID: DR00223
INTEDE ID: DR1445
ACDINA ID: D00608

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DT56EKP	NTCP_HUMAN	Substrate	[11]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[11]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[12]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Drug Response	[9]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Drug Response	[8]
Kinesin-like protein KIF6 (KIF6)	OTDH3MR4	KIF6_HUMAN	Drug Response	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Arteriosclerosis

ICD Disease Classification

BD40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
HMG-CoA reductase (HMGCR)	DTT	HMGCR	1.01E-05	0.65	1.53
Organic anion transporter 3 (SLC22A8)	DTP	OAT3	1.54E-03	-5.09E-01	-1.49E+00
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.29E-14	-7.08E-01	-1.99E+00
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTP	OATP2B1	3.80E-01	-1.23E-02	-5.33E-02
Breast cancer resistance protein (ABCG2)	DTP	BCRP	2.28E-08	-3.66E-01	-8.07E-01
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	4.30E-02	-2.29E-01	-9.10E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTP	OATP1A2	7.28E-02	-7.13E-02	-4.55E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	1.65E-01	-6.07E-02	-3.77E-01
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DTP	NTCP	7.48E-02	-5.70E-02	-2.14E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	3.27E-01	-5.78E-02	-3.84E-01
Cytochrome P450 1B1 (CYP1B1)	DME	CYP1B1	1.27E-09	2.24E+00	2.07E+00
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.63E-03	-1.18E-01	-3.80E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.24E-05	-3.48E-01	-1.34E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rosuvastatin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[16]
Gemfibrozil	DMD8Q3J	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[17]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Rosuvastatin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[18]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Rosuvastatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[19]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Rosuvastatin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[20]
-----------

Coadministration of a Drug Treating the Disease Different from Rosuvastatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Rosuvastatin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[19]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[21]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Rosuvastatin due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[21]
Ag-221	DMS0ZBI	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[19]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Rosuvastatin caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
PF-04449913	DMSB068	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[21]
MK-8228	DMOB58Q	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[23]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Rosuvastatin due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[17]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Rosuvastatin caused by Eslicarbazepine mediated induction of UGT.	Epilepsy/seizure [8A61-8A6Z]	[21]
Simeprevir	DMLUA9D	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[24]
GS-9857	DMYU6P5	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by GS-9857.	Hepatitis virus infection [1E50-1E51]	[25]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Rosuvastatin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Lopinavir	DMITQS0	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Darunavir	DMN3GCH	Major	Decreased clearance of Rosuvastatin due to the transporter inhibition by Darunavir.	Human immunodeficiency virus disease [1C60-1C62]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Rosuvastatin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[29]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Rosuvastatin and Idelalisib.	Mature B-cell leukaemia [2A82]	[30]
Dabrafenib	DMX6OE3	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Dabrafenib.	Melanoma [2C30]	[19]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[31]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[32]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[19]
Tedizolid	DMG2SKR	Moderate	Decreased clearance of Rosuvastatin due to the transporter inhibition by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[21]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Meglumine	E00181	8567	Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Calcium hydrogenphosphate	E00294	24441	Diluent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium carbonate monohydrate	E00454	2735133	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 33 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rosuvastatin 10 mg tablet	10 mg	Oral Tablet	Oral
Rosuvastatin 20 mg tablet	20 mg	Oral Tablet	Oral
Rosuvastatin 40 mg tablet	40 mg	Oral Tablet	Oral
Rosuvastatin 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Rosuvastatin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2954).
3	Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003 Nov;25(11):2822-35.
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
8	ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
9	Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004 Jun 16;291(23):2821-7. doi: 10.1001/jama.291.23.2821.
10	New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
11	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
12	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
13	The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
14	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
15	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
16	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
17	Product Information. Crestor (rosuvastatin). AstraZeneca Pharma Inc, Mississauga, ON.
18	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
24	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
25	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
26	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
27	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
28	Neuvonen PJ, Niemi M, Backman JT "Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance." Clin Pharmacol Ther 80 (2006): 565-81. [PMID: 17178259]
29	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
30	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
31	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
32	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.